Budget Impact Analysis of Bimekizumab for the Treatment of Axial Spondyloarthritis (axSpA) in Greece
Author(s)
Koulentaki M1, Ravanidis S2, Daoussis D3, Dimitroulas T4, Papagoras C5, Sfikakis P6, Kountouris V7, Feretos M7, Kourlaba G8, Lyris N9, Willems D10
1ECONCARE LP, Athens, Greece, 2ECONCARE LP, Athens, Attica, Greece, 3University of Patras Medical School, Patras University Hospital, Dept. Of Rheumatology, Patra, Greece, 4Medical School, Aristotle University of Thessaloniki, 4th Department of Internal Medicine Hippokration Hospital, Thessaloniki, Greece, 5Democritus University of Thrace, st Department of Internal Medicine, Alexandroupolis, Greece, 6Medical School, National and Kapodistrian University of Athens, Internal Medicine & Rheumatology, Athens, Greece, 7UCB Pharma, Athens, Greece, 8University of Peloponnese, School of Health Sciences, 44 KIFISSIAS, A1, Greece, 9UCB Pharma, Slough, UK, 10UCB Pharma, Brussels, Belgium
Presentation Documents
OBJECTIVES: To assess the potential budgetary impact of integrating bimekizumab, a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)-17F in addition to IL-17A, into the available treatment options available for adult patients with axial spondyloarthritis (axSpA) in Greece, who are biologic/ targeted synthetic disease-modifying antirheumatic drugs (b/ts DMARD)-naïve and b/ts DMARD-experienced, alongside currently available biologic therapies and small molecules, such as Janus kinase (JAK) inhibitors.
METHODS: A comprehensive budget impact analysis was conducted, from the perspective of a public payer, projecting the financial consequences over five years (2025-2029). The model incorporated key parameters, including epidemiological data on axSpA patients in Greece, various market share scenarios both with and without bimekizumab, efficacy inputs based on the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), using data from a published network meta-analysis. As the analysis was conducted from the public payer perspective, only direct unit costs were considered. All unit costs were anchored to 2023 values. Epidemiological data were sourced from officially published studies and were supplemented with insights from local clinical experts. Market share projections were based on estimations.
RESULTS: The eligible patient population ranged from 6,738 patients in the first year to 7,053 in the fifth year. The introduction of bimekizumab to the axSpA market is expected to progressively increase, the number of patients treated with bimekizumab, with an estimated number of patients rising from 131 in 2025 to 427 patients in 2029. Considering the total budget impact, the inclusion of bimekizumab resulted in an average additional cost of €267 per patient per year. Over a five-year period, the annual average budget impact was calculated to be €1,851,487.
CONCLUSIONS: The study reveals that introducing bimekizumab to the Greek axSpA market will enhance patient health outcomes without causing budgetary strain.
Conference/Value in Health Info
Value in Health, Volume 27, Issue 12, S2 (December 2024)
Code
EE454
Topic
Economic Evaluation, Epidemiology & Public Health
Topic Subcategory
Budget Impact Analysis
Disease
Biologics & Biosimilars